Cargando…

Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis).

OBJECTIVE: To evaluate the safety and efficacy of intravenous and oral ofloxacin monotherapy in the treatment of laparoscopically documented acute pelvic inflammatory disease (PID). METHODS: This study was conducted as an open-label, phase-III, uncontrolled, multicenter study. Patients identified wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Peipert, J F, Sweet, R L, Walker, C K, Kahn, J, Rielly-Gauvin, K
Formato: Texto
Lenguaje:English
Publicado: 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1784735/
https://www.ncbi.nlm.nih.gov/pubmed/10371472
http://dx.doi.org/10.1002/(SICI)1098-0997(1999)7:3<138::AID-IDOG5>3.0.CO;2-9
_version_ 1782132091781120000
author Peipert, J F
Sweet, R L
Walker, C K
Kahn, J
Rielly-Gauvin, K
author_facet Peipert, J F
Sweet, R L
Walker, C K
Kahn, J
Rielly-Gauvin, K
author_sort Peipert, J F
collection PubMed
description OBJECTIVE: To evaluate the safety and efficacy of intravenous and oral ofloxacin monotherapy in the treatment of laparoscopically documented acute pelvic inflammatory disease (PID). METHODS: This study was conducted as an open-label, phase-III, uncontrolled, multicenter study. Patients identified with laparoscopic findings of salpingitis were treated with 400 mg of intravenous ofloxacin every 12 hours followed by 400 mg of oral ofloxacin every 12 hours for 10 to 14 days. Patients were evaluated five times for clinical and microbial efficacy. Since laparoscopy was performed only at admission, pathogens identified laparoscopically were presumed eradicated if they were present on the laparoscopic culture and the patient was clinically cured or improved at final evaluation. RESULTS: Of the 70 patients evaluable for safety (intent-to-treat population), the mean age was 25.6 years. Sixty-one of 70 patients (87%) were cured, one improved, one did not improve, and seven were unevaluable because they discontinued study participation. Fifty-one were evaluable for clinical efficacy: 50 (98%) were cured and one did not improve. Sixteen were evaluable for expanded microbiological efficacy: three had documented Neisseria gonorrhoeae; 12, Chlamydia trachomatis; and one, a mixed infection of both organisms. All cervical, laparoscopic, and endometrial cultured pathogens, including N. gonorrhoeae and C. trachomatis, were eradicated or presumed eradicated at the posttherapy visit. No serious or unexpected adverse events occurred. CONCLUSIONS: Ofloxacin monotherapy was effective and well tolerated in the treatment of laparoscopically proven PID in a geographically diverse population. Future studies are necessary to evaluate long-term outcomes and sequelae of PID treatment with single agent therapy.
format Text
id pubmed-1784735
institution National Center for Biotechnology Information
language English
publishDate 1999
record_format MEDLINE/PubMed
spelling pubmed-17847352007-02-05 Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis). Peipert, J F Sweet, R L Walker, C K Kahn, J Rielly-Gauvin, K Infect Dis Obstet Gynecol Research Article OBJECTIVE: To evaluate the safety and efficacy of intravenous and oral ofloxacin monotherapy in the treatment of laparoscopically documented acute pelvic inflammatory disease (PID). METHODS: This study was conducted as an open-label, phase-III, uncontrolled, multicenter study. Patients identified with laparoscopic findings of salpingitis were treated with 400 mg of intravenous ofloxacin every 12 hours followed by 400 mg of oral ofloxacin every 12 hours for 10 to 14 days. Patients were evaluated five times for clinical and microbial efficacy. Since laparoscopy was performed only at admission, pathogens identified laparoscopically were presumed eradicated if they were present on the laparoscopic culture and the patient was clinically cured or improved at final evaluation. RESULTS: Of the 70 patients evaluable for safety (intent-to-treat population), the mean age was 25.6 years. Sixty-one of 70 patients (87%) were cured, one improved, one did not improve, and seven were unevaluable because they discontinued study participation. Fifty-one were evaluable for clinical efficacy: 50 (98%) were cured and one did not improve. Sixteen were evaluable for expanded microbiological efficacy: three had documented Neisseria gonorrhoeae; 12, Chlamydia trachomatis; and one, a mixed infection of both organisms. All cervical, laparoscopic, and endometrial cultured pathogens, including N. gonorrhoeae and C. trachomatis, were eradicated or presumed eradicated at the posttherapy visit. No serious or unexpected adverse events occurred. CONCLUSIONS: Ofloxacin monotherapy was effective and well tolerated in the treatment of laparoscopically proven PID in a geographically diverse population. Future studies are necessary to evaluate long-term outcomes and sequelae of PID treatment with single agent therapy. 1999 /pmc/articles/PMC1784735/ /pubmed/10371472 http://dx.doi.org/10.1002/(SICI)1098-0997(1999)7:3<138::AID-IDOG5>3.0.CO;2-9 Text en
spellingShingle Research Article
Peipert, J F
Sweet, R L
Walker, C K
Kahn, J
Rielly-Gauvin, K
Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis).
title Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis).
title_full Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis).
title_fullStr Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis).
title_full_unstemmed Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis).
title_short Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis).
title_sort evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis).
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1784735/
https://www.ncbi.nlm.nih.gov/pubmed/10371472
http://dx.doi.org/10.1002/(SICI)1098-0997(1999)7:3<138::AID-IDOG5>3.0.CO;2-9
work_keys_str_mv AT peipertjf evaluationofofloxacininthetreatmentoflaparoscopicallydocumentedacutepelvicinflammatorydiseasesalpingitis
AT sweetrl evaluationofofloxacininthetreatmentoflaparoscopicallydocumentedacutepelvicinflammatorydiseasesalpingitis
AT walkerck evaluationofofloxacininthetreatmentoflaparoscopicallydocumentedacutepelvicinflammatorydiseasesalpingitis
AT kahnj evaluationofofloxacininthetreatmentoflaparoscopicallydocumentedacutepelvicinflammatorydiseasesalpingitis
AT riellygauvink evaluationofofloxacininthetreatmentoflaparoscopicallydocumentedacutepelvicinflammatorydiseasesalpingitis